bumetanide has been researched along with Aura in 33 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity." | 9.51 | Clarifications regarding bumetanide for neonatal seizures. ( Staley, KJ, 2022) |
| "Bumetanide, an inhibitor of the sodium-potassium-chloride cotransporter-1, has been suggested as an adjunct to phenobarbital for treating neonatal seizures." | 9.41 | Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies. ( Athikarisamy, S; Farhat, A; Ghosh, S; Nagarajan, L; Rakshasbhuvankar, A; Rao, S, 2023) |
| "In his editorial, Kevin Staley criticizes our recent work demonstrating the lack of effect of bumetanide in a novel model of neonatal seizures." | 8.12 | Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel. ( Kaila, K; Löscher, W, 2022) |
| "Kaila, Löscher, and colleagues report that phenobarbital (PHB) and midazolam (MDZ) attenuate neonatal seizures following birth asphyxia, but the former only when applied before asphyxia and the latter before or after the triggering insult." | 8.02 | Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details. ( Ben-Ari, Y; Delpire, E, 2021) |
| "There is considerable interest in using bumetanide, a chloride importer Na-K-Cl cotransporter antagonist, for treatment of neurological diseases, such as epilepsy or ischemic and traumatic brain injury, that may involve deranged cellular chloride homeostasis." | 7.80 | A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. ( Brandt, C; Brunhofer, G; Erker, T; Feit, PW; Gabriel, M; Kaila, K; Lindfors, J; Löscher, W; Töllner, K; Töpfer, M, 2014) |
| "For bumetanide, it has been suggested that inhibition of the NKCC isoform NKCC1 in the membrane of brain neurons may be involved; however, NKCC1 is expressed by virtually all cell types in the brain, which makes any specific targeting of neuronal NKCC1 by bumetanide impossible." | 5.91 | The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia. ( Gramer, M; Kirchhoff, L; Löscher, W; Schmidt, R; Welzel, B, 2023) |
| "A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity." | 5.51 | Clarifications regarding bumetanide for neonatal seizures. ( Staley, KJ, 2022) |
| "Bumetanide, an inhibitor of the sodium-potassium-chloride cotransporter-1, has been suggested as an adjunct to phenobarbital for treating neonatal seizures." | 5.41 | Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies. ( Athikarisamy, S; Farhat, A; Ghosh, S; Nagarajan, L; Rakshasbhuvankar, A; Rao, S, 2023) |
| "Literature searches were conducted utilizing PubMed and MEDLINE databases employing combinations of search terms including, but not limited to, "epilepsy", "refractory", "seizure", and the following medications: acetazolamide, amantadine, bumetanide, imipramine, lidocaine, verapamil, and various stimulants." | 4.95 | Outside the box: Medications worth considering when traditional antiepileptic drugs have failed. ( Perry, MS; Turner, AL, 2017) |
| "In his editorial, Kevin Staley criticizes our recent work demonstrating the lack of effect of bumetanide in a novel model of neonatal seizures." | 4.12 | Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel. ( Kaila, K; Löscher, W, 2022) |
| "Kaila, Löscher, and colleagues report that phenobarbital (PHB) and midazolam (MDZ) attenuate neonatal seizures following birth asphyxia, but the former only when applied before asphyxia and the latter before or after the triggering insult." | 4.02 | Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details. ( Ben-Ari, Y; Delpire, E, 2021) |
| "Based on the potential role of Na-K-Cl cotransporters (NKCCs) in epileptic seizures, the loop diuretic bumetanide, which blocks the NKCC1 isoforms NKCC1 and NKCC2, has been tested as an adjunct with phenobarbital to suppress seizures." | 3.88 | Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy. ( Brandt, C; Feit, PW; Hampel, P; Kaila, K; Kalesse, M; Kipper, A; Löscher, W; Lykke, K; MacAulay, N; Paavilainen, P; Puskarjov, M; Römermann, K; Seja, P; Spoljaric, I; Toft-Bertelsen, TL; Töllner, K, 2018) |
| "There is considerable interest in using bumetanide, a chloride importer Na-K-Cl cotransporter antagonist, for treatment of neurological diseases, such as epilepsy or ischemic and traumatic brain injury, that may involve deranged cellular chloride homeostasis." | 3.80 | A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. ( Brandt, C; Brunhofer, G; Erker, T; Feit, PW; Gabriel, M; Kaila, K; Lindfors, J; Löscher, W; Töllner, K; Töpfer, M, 2014) |
| "Neonatal stroke is the second cause of acute symptomatic neonatal seizures after hypoxic-ischemic encephalopathy." | 2.82 | Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review. ( Criscione, R; Falsaperla, R; Marino, S; Pisani, F; Praticò, A; Ruggieri, M; Sortino, V, 2022) |
| "Levetiracetam has been used in children and infants with good efficacy, an excellent safety profile, and near-ideal pharmacokinetic characteristics." | 2.49 | Newly emerging therapies for neonatal seizures. ( Mangum, B; Pressler, RM, 2013) |
| "For bumetanide, it has been suggested that inhibition of the NKCC isoform NKCC1 in the membrane of brain neurons may be involved; however, NKCC1 is expressed by virtually all cell types in the brain, which makes any specific targeting of neuronal NKCC1 by bumetanide impossible." | 1.91 | The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia. ( Gramer, M; Kirchhoff, L; Löscher, W; Schmidt, R; Welzel, B, 2023) |
| "Angelman syndrome is a neurodevelopmental disorder caused by loss of function of the maternally expressed UBE3A gene." | 1.91 | Imbalanced expression of cation-chloride cotransporters as a potential therapeutic target in an Angelman syndrome mouse model. ( Egawa, K; Fukuda, A; Nishio, S; Sato, D; Shiraishi, H; Takahashi, Y; Watanabe, M, 2023) |
| "Epilepsy was induced by pilocarpine, which was shown to produce long-lasting increases in NKCC1 in the hippocampus, whereas MEST did not alter NKCC1 mRNA in this region." | 1.62 | Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice. ( Gailus, B; Gericke, B; Hampel, P; Johne, M; Kaczmarek, E; Löscher, W; Römermann, K, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (18.18) | 29.6817 |
| 2010's | 16 (48.48) | 24.3611 |
| 2020's | 11 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Staley, KJ | 1 |
| Kaila, K | 5 |
| Löscher, W | 9 |
| Sortino, V | 1 |
| Praticò, A | 1 |
| Marino, S | 1 |
| Criscione, R | 1 |
| Ruggieri, M | 1 |
| Pisani, F | 1 |
| Falsaperla, R | 1 |
| Welzel, B | 2 |
| Schmidt, R | 1 |
| Kirchhoff, L | 1 |
| Gramer, M | 1 |
| Johne, M | 2 |
| Egawa, K | 1 |
| Watanabe, M | 1 |
| Shiraishi, H | 1 |
| Sato, D | 1 |
| Takahashi, Y | 1 |
| Nishio, S | 1 |
| Fukuda, A | 1 |
| Rao, S | 1 |
| Farhat, A | 1 |
| Rakshasbhuvankar, A | 1 |
| Athikarisamy, S | 1 |
| Ghosh, S | 1 |
| Nagarajan, L | 1 |
| Auer, T | 1 |
| Schreppel, P | 1 |
| Erker, T | 3 |
| Schwarzer, C | 1 |
| Hampel, P | 2 |
| Römermann, K | 2 |
| Gailus, B | 1 |
| Gericke, B | 1 |
| Kaczmarek, E | 1 |
| Ben-Ari, Y | 3 |
| Delpire, E | 1 |
| Turner, AL | 1 |
| Perry, MS | 1 |
| Brandt, C | 2 |
| Seja, P | 1 |
| Töllner, K | 3 |
| Kalesse, M | 1 |
| Kipper, A | 1 |
| Feit, PW | 3 |
| Lykke, K | 2 |
| Toft-Bertelsen, TL | 1 |
| Paavilainen, P | 1 |
| Spoljaric, I | 1 |
| Puskarjov, M | 2 |
| MacAulay, N | 2 |
| Yuan, Y | 1 |
| O'Malley, HA | 1 |
| Smaldino, MA | 1 |
| Bouza, AA | 1 |
| Hull, JM | 1 |
| Isom, LL | 1 |
| Pressler, RM | 1 |
| Mangum, B | 1 |
| Töpfer, M | 1 |
| Brunhofer, G | 1 |
| Gabriel, M | 1 |
| Lindfors, J | 1 |
| Hamidi, S | 1 |
| Avoli, M | 1 |
| Marguet, SL | 1 |
| Le-Schulte, VT | 1 |
| Merseburg, A | 1 |
| Neu, A | 1 |
| Eichler, R | 1 |
| Jakovcevski, I | 1 |
| Ivanov, A | 1 |
| Hanganu-Opatz, IL | 1 |
| Bernard, C | 1 |
| Morellini, F | 1 |
| Isbrandt, D | 1 |
| Koyama, R | 1 |
| MacKenzie, G | 1 |
| O'Toole, KK | 1 |
| Moss, SJ | 1 |
| Maguire, J | 1 |
| Berkovic, SF | 1 |
| Nardou, R | 2 |
| Khalilov, I | 2 |
| Tyzio, R | 1 |
| Represa, A | 1 |
| Crepel, V | 1 |
| Zilberter, Y | 1 |
| Rheims, S | 1 |
| Aniksztejn, L | 1 |
| Cossart, R | 1 |
| Mukhtarov, M | 1 |
| Minlebaev, M | 1 |
| Epsztein, J | 1 |
| Milh, M | 1 |
| Becq, H | 1 |
| Jorquera, I | 1 |
| Bulteau, C | 1 |
| Fohlen, M | 1 |
| Oliver, V | 1 |
| Dulac, O | 1 |
| Dorfmüller, G | 1 |
| Delalande, O | 1 |
| Khazipov, R | 1 |
| Edwards, DA | 1 |
| Shah, HP | 1 |
| Cao, W | 1 |
| Gravenstein, N | 1 |
| Seubert, CN | 1 |
| Martynyuk, AE | 1 |
| Almeida, AC | 1 |
| Scorza, FA | 1 |
| Rodrigues, AM | 1 |
| Arida, RM | 1 |
| Carlesso, FN | 1 |
| Batista, AG | 1 |
| Duarte, MA | 1 |
| DaCosta, JC | 1 |
| Hochman, DW | 1 |
| Vargas, E | 1 |
| Petrou, S | 1 |
| Reid, CA | 1 |
| Jin, X | 1 |
| Huguenard, JR | 1 |
| Prince, DA | 1 |
| Margineanu, DG | 1 |
| Klitgaard, H | 1 |
| Frey, HH | 1 |
| Kilb, W | 1 |
| Sinning, A | 1 |
| Luhmann, HJ | 1 |
9 reviews available for bumetanide and Aura
| Article | Year |
|---|---|
Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review.
Topics: Anticonvulsants; Bumetanide; Epilepsy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Levetirac | 2022 |
Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies.
Topics: Aminoglycosides; Animals; Anticonvulsants; Bumetanide; Epilepsy; Hearing Loss; Humans; Infant; Infan | 2023 |
Impaired chloride homeostasis in epilepsy: Molecular basis, impact on treatment, and current treatment approaches.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Bumetanide; Chlorides; Diuretics; Drug Development; E | 2020 |
Outside the box: Medications worth considering when traditional antiepileptic drugs have failed.
Topics: Amantadine; Anticonvulsants; Bumetanide; Central Nervous System Stimulants; Epilepsy; Humans; Imipra | 2017 |
Newly emerging therapies for neonatal seizures.
Topics: Animals; Anticonvulsants; Brain; Bumetanide; Child Development; Epilepsy; Fructose; Humans; Infant, | 2013 |
Dentate Circuitry as a Model to Study Epileptogenesis.
Topics: Animals; Anticonvulsants; Bumetanide; Dentate Gyrus; Epilepsy; Humans | 2016 |
Epilepsy research in 2016: new treatment directions.
Topics: Biomedical Research; Bumetanide; Drug Resistant Epilepsy; Epilepsy; Epilepsy, Temporal Lobe; Humans; | 2017 |
The extracellular space and epileptic activity in the adult brain: explaining the antiepileptic effects of furosemide and bumetanide.
Topics: Animals; Anticonvulsants; Brain; Bumetanide; Diuretics; Epilepsy; Extracellular Space; Furosemide; H | 2012 |
Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments.
Topics: Adult; Animals; Anticonvulsants; Brain; Bumetanide; Diuretics; Epilepsy; gamma-Aminobutyric Acid; Hu | 2013 |
1 trial available for bumetanide and Aura
| Article | Year |
|---|---|
Clarifications regarding bumetanide for neonatal seizures.
Topics: Bumetanide; Epilepsy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Seizures; Sodium Potassium | 2022 |
23 other studies available for bumetanide and Aura
| Article | Year |
|---|---|
Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel.
Topics: Bumetanide; Epilepsy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Seizures; Sodium Potassium | 2022 |
The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Topics: Animals; Asphyxia; Bumetanide; Diuretics; Epilepsy; Furosemide; Rats; Sodium Potassium Chloride Symp | 2023 |
Bumetanide potentiates the anti-seizure and disease-modifying effects of midazolam in a noninvasive rat model of term birth asphyxia.
Topics: Animals; Anticonvulsants; Asphyxia; Asphyxia Neonatorum; Bumetanide; Epilepsy; Humans; Infant, Newbo | 2023 |
Imbalanced expression of cation-chloride cotransporters as a potential therapeutic target in an Angelman syndrome mouse model.
Topics: Angelman Syndrome; Animals; Bumetanide; Chlorides; Epilepsy; Mice; Receptors, GABA-A; Sodium-Potassi | 2023 |
Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Topics: Animals; Anticonvulsants; Bumetanide; Drug Therapy, Combination; Epilepsy; Female; Mice; Phenobarbit | 2021 |
Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details.
Topics: Animals; Anticonvulsants; Bumetanide; Epilepsy; Humans; Midazolam; Phenobarbital; Prohibitins; Seizu | 2021 |
Reply to the commentary by Ben-Ari and Delpire: Bumetanide and neonatal seizures: Fiction versus reality.
Topics: Animals; Bumetanide; Epilepsy; Rats; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Solut | 2021 |
Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Topics: Animals; Anticonvulsants; Benzylamines; Brain; Bumetanide; Drug Evaluation, Preclinical; Drug Synerg | 2018 |
Delayed maturation of GABAergic signaling in the Scn1a and Scn1b mouse models of Dravet Syndrome.
Topics: Animals; Bumetanide; Death, Sudden; Disease Models, Animal; Epilepsies, Myoclonic; Epilepsy; gamma-A | 2019 |
A novel prodrug-based strategy to increase effects of bumetanide in epilepsy.
Topics: Action Potentials; Animals; Animals, Newborn; Brain; Bumetanide; Convulsants; Disease Models, Animal | 2014 |
KCC2 function modulates in vitro ictogenesis.
Topics: 4-Aminopyridine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Bumetanide; Cerebral Cortex; Disease | 2015 |
Treatment during a vulnerable developmental period rescues a genetic epilepsy.
Topics: Animals; Animals, Newborn; Behavior, Animal; Body Weight; Bumetanide; CA1 Region, Hippocampal; Cogni | 2015 |
The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A.
Topics: Animals; Anticonvulsants; Bumetanide; Diuretics; Epilepsy; Humans; Oocytes; Solute Carrier Family 12 | 2016 |
Compromised GABAergic inhibition contributes to tumor-associated epilepsy.
Topics: Animals; Brain; Brain Neoplasms; Bumetanide; Cell Line, Tumor; Disease Models, Animal; Epilepsy; gam | 2016 |
Bumetanide, an NKCC1 antagonist, does not prevent formation of epileptogenic focus but blocks epileptic focus seizures in immature rat hippocampus.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Animals, Newborn; Bicuculline; Bio | 2009 |
Inhibitory actions of the gamma-aminobutyric acid in pediatric Sturge-Weber syndrome.
Topics: Action Potentials; Bumetanide; Cerebral Cortex; Diazepam; Epilepsy; Excitatory Amino Acid Antagonist | 2009 |
Bumetanide alleviates epileptogenic and neurotoxic effects of sevoflurane in neonatal rat brain.
Topics: Anesthesia, Inhalation; Anesthetics, Inhalation; Animals; Animals, Newborn; Blotting, Western; Bumet | 2010 |
Combined effect of bumetanide, bromide, and GABAergic agonists: an alternative treatment for intractable seizures.
Topics: Bromides; Bumetanide; Drug Therapy, Combination; Epilepsy; GABA Agonists; Humans; Sodium Potassium C | 2011 |
Genetic and pharmacological modulation of giant depolarizing potentials in the neonatal hippocampus associates with increased seizure susceptibility.
Topics: Animals; Animals, Newborn; Bumetanide; Disease Models, Animal; Epilepsy; Hippocampus; Mice; Mice, In | 2013 |
Impaired Cl- extrusion in layer V pyramidal neurons of chronically injured epileptogenic neocortex.
Topics: Animals; Bumetanide; Chlorides; Chronic Disease; Epilepsy; K Cl- Cotransporters; Membrane Potentials | 2005 |
Differential effects of cation-chloride co-transport-blocking diuretics in a rat hippocampal slice model of epilepsy.
Topics: Animals; Anticonvulsants; Bumetanide; Disease Models, Animal; Diuretics; Dose-Response Relationship, | 2006 |
Antiepileptic effect of loop diuretics? Comment to "Differential effects of cation-chloride co-transport-blocking diuretics in a rat hippocampal slice model of epilepsy" by Margineanu, Klitgaard, Epilepsy Res. 69 (2006) 93-99.
Topics: Animals; Bumetanide; Diuretics; Epilepsy; Ethacrynic Acid; Evoked Potentials; Furosemide; Rats | 2006 |
Model-specific effects of bumetanide on epileptiform activity in the in-vitro intact hippocampus of the newborn mouse.
Topics: Animals; Animals, Newborn; Bumetanide; Chloride Channels; Disease Models, Animal; Epilepsy; Hippocam | 2007 |